At a glance
A biotechnology company devoted to transforming the lives of cancer patients by pioneering the development of next generation immune oncology (IO) therapies. The company’s technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs).
Investors
Integra Holdings, aMoon, Peregrine and Marius Nacht
MORE COMPANIES
